“SRDX beat consensus F4Q18 revenue and EPS. Management provided FY19 revenue guidance that was above consensus while adjusted EPS guidance was below consensus. Revenue growth slowed to 14.9% in in F3Q18. SRDX’s 3Q18 gross margin was down 120 bps Y/Y and its non-GAAP operating margin was down 1,130 bps Y/Y. Given FY19 revenue guidance that we think is achievable and likely conservative and continued progress with SRDX’s DCB program, we reiterate our Buy rating.”
According to TipRanks.com, Matson is a 5-star analyst with an average return of 11.8% and a 63.9% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Cardiovascular Systems, and Zimmer Biomet Holdings.
Currently, the analyst consensus on SurModics is a Moderate Buy with an average price target of $77.
Based on SurModics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $2.68 million. In comparison, last year the company had a net profit of $400K.
Based on the recent corporate insider activity of 67 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SurModics, Inc. engages in the provision of medical device and in vitro diagnostic technologies to the healthcare industry. It operates through the Medical Device and In Vitro Diagnostics segments.